Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer
- 1 February 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Dissecting the Immunobiological Effects of Bacillus Calmette-Guérin (BCG) In Vitro: Evidence of a Distinct BCG-Activated Killer (BAK) Cell PhenomenonJournal of Urology, 1993
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder WallJournal of Urology, 1992
- BCG treatment and the importance of an inflammatory responseUrological Research, 1992
- Current perspectives on diagnosis and treatment of superficial bladder cancerUrology, 1992
- Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-GuérinCancer Immunology, Immunotherapy, 1991
- Radio-Immunoassay Detection of Interferon-Gamma in Urine after Intravesical Evans BCG TherapyJournal of Urology, 1990
- Effects of Local Bacillus Calmette-Guerin Therapy in Patients with Bladder Carcinoma on Immunocompetent Cells of the Bladder WallJournal of Urology, 1990
- Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinomaCytokine, 1990
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986